Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gottfried Novacek

Showing results (51-60 of 70) with videos related to

Pageof 7
Sort By:
Journal of Crohn'S & Colitis|October 7, 2016
A Randomised, Double-blind, Placebo-controlled Trial of Trichuris suis ova in Active Crohn's DiseaseJürgen Schölmerich, Klaus Fellermann, Frank W Seibold, et al.
Frontiers in Medicine|February 27, 2023
The accelerated waning of immunity and reduced effect of booster in patients treated with bDMARD and tsDMARD after SARS-CoV-2 mRNA vaccinationSelma Tobudic, Elisabeth Simader, Thomas Deimel, et al.
Gastroenterology|June 16, 2010
Inflammatory bowel disease is a risk factor for recurrent venous thromboembolismGottfried Novacek, Ansgar Weltermann, Anna Sobala, et al.
Journal of Crohn'S & Colitis|November 7, 2012
Clinical presentation of venous thromboembolism in inflammatory bowel diseasePavol Papay, Wolfgang Miehsler, Herbert Tilg, et al.
Wiener Klinische Wochenschrift|February 5, 2019
Diagnostic delay in patients with inflammatory bowel disease in AustriaGottfried Novacek, Hans Peter Gröchenig, Thomas Haas, et al.
Ebiomedicine|September 6, 2023
Lower magnitude and faster waning of antibody responses to SARS-CoV-2 vaccination in anti-TNF-α-treated IBD patients are linked to lack of activation and expansion of cTfh1 cells and impaired B memory cell formationErika Garner-Spitzer, Angelika Wagner, Venugopal Gudipati, et al.
Frontiers in Immunology|May 31, 2022
SARS-CoV-2-mRNA Booster Vaccination Reverses Non-Responsiveness and Early Antibody Waning in Immunocompromised Patients - A Phase Four Study Comparing Immune Responses in Patients With Solid Cancers, Multiple Myeloma and Inflammatory Bowel DiseaseAngelika Wagner, Erika Garner-Spitzer, Anna-Margarita Schötta, et al.
European Journal of Gastroenterology & Hepatology|September 10, 2019
Prevalence and indicators of use of complementary and alternative medicine in Austrian patients with inflammatory bowel diseaseHans Peter Gröchenig, Thomas Waldhör, Thomas Haas, et al.
Inflammatory Bowel Diseases|March 26, 2011
Infliximab or cyclosporine as rescue therapy in hospitalized patients with steroid-refractory ulcerative colitis: a retrospective observational studyMats Sjöberg, Andrea Walch, Mina Meshkat, et al.
Inflammatory Bowel Diseases|January 2, 2021
Inflammatory Bowel Disease and Risk of Major Bleeding During Anticoagulation for Venous ThromboembolismSusanna Scharrer, Christian Primas, Sabine Eichinger, et al.
Pageof 7

Showing results (51-60 of 70) with videos related to

Sort By:
Pageof 7
Journal of Crohn'S & Colitis|October 7, 2016
A Randomised, Double-blind, Placebo-controlled Trial of Trichuris suis ova in Active Crohn's DiseaseJürgen Schölmerich, Klaus Fellermann, Frank W Seibold, et al.
Frontiers in Medicine|February 27, 2023
The accelerated waning of immunity and reduced effect of booster in patients treated with bDMARD and tsDMARD after SARS-CoV-2 mRNA vaccinationSelma Tobudic, Elisabeth Simader, Thomas Deimel, et al.
Gastroenterology|June 16, 2010
Inflammatory bowel disease is a risk factor for recurrent venous thromboembolismGottfried Novacek, Ansgar Weltermann, Anna Sobala, et al.
Journal of Crohn'S & Colitis|November 7, 2012
Clinical presentation of venous thromboembolism in inflammatory bowel diseasePavol Papay, Wolfgang Miehsler, Herbert Tilg, et al.
Wiener Klinische Wochenschrift|February 5, 2019
Diagnostic delay in patients with inflammatory bowel disease in AustriaGottfried Novacek, Hans Peter Gröchenig, Thomas Haas, et al.
Ebiomedicine|September 6, 2023
Lower magnitude and faster waning of antibody responses to SARS-CoV-2 vaccination in anti-TNF-α-treated IBD patients are linked to lack of activation and expansion of cTfh1 cells and impaired B memory cell formationErika Garner-Spitzer, Angelika Wagner, Venugopal Gudipati, et al.
Frontiers in Immunology|May 31, 2022
SARS-CoV-2-mRNA Booster Vaccination Reverses Non-Responsiveness and Early Antibody Waning in Immunocompromised Patients - A Phase Four Study Comparing Immune Responses in Patients With Solid Cancers, Multiple Myeloma and Inflammatory Bowel DiseaseAngelika Wagner, Erika Garner-Spitzer, Anna-Margarita Schötta, et al.
European Journal of Gastroenterology & Hepatology|September 10, 2019
Prevalence and indicators of use of complementary and alternative medicine in Austrian patients with inflammatory bowel diseaseHans Peter Gröchenig, Thomas Waldhör, Thomas Haas, et al.
Inflammatory Bowel Diseases|March 26, 2011
Infliximab or cyclosporine as rescue therapy in hospitalized patients with steroid-refractory ulcerative colitis: a retrospective observational studyMats Sjöberg, Andrea Walch, Mina Meshkat, et al.
Inflammatory Bowel Diseases|January 2, 2021
Inflammatory Bowel Disease and Risk of Major Bleeding During Anticoagulation for Venous ThromboembolismSusanna Scharrer, Christian Primas, Sabine Eichinger, et al.
Pageof 7